[Cardiac rhythm disorders. 2. Therapy].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001146:Arrhythmia, Sinus / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001919:Bradycardia / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004554:Electric Countershock; D006327:Heart Block / Q000188:drug therapy; D006336:Heart Massage; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use; D009921:Metaproterenol / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D004071:Digitalis Glycosides; D006827:Hydantoins; D009921:Metaproterenol; D012110:Reserpine; D008012:Lidocaine; D011803:Quinine; D011342:Procainamide
Kardiale Rhythmusstörungen. 2. Therapie.